Benzinga | Jul 28, 2021 09:00AM EDT

EXCLUSIVE: Ampio Pharma Highlights Upcoming Presentation Of Data For Ampion At Int'l. Congress On Systemic Lupus Ertyhematosus, Oct. 6-9, 2021

Ampio Pharmaceuticals to Present at the 14

th

International Congress on Systemic Lupus

Erythematosus (LUPUS 2021) & 6

th

International Congress on Controversies in

Rheumatology and Autoimmunity (CORA)

ENGLEWOOD, CO, July 28, 2021

--

Ampio Pharmaceuticals

(NYSE American:

AMPE), a biopharmaceutical company focused on the advancement of immunology-

based therapies for prevalent inflammatory conditions, today announced details on

the

C

ompany's

abstract

presentation, "Significant Inhibition of the TLR7/CXCL10

Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and

Lupus Nephritis," being given virtually at the

14th International Congress on

Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on

Controversies in Rheumatology and Autoimmunity (CORA)

on October 6-9, 2021.

Ampio's presentation is based on the Company's analysis that Ampio's drug

candidate, Ampion(tm), currently under clinical investigation for the treatment of

osteoarthritis and the hyper-inflammation observed with severe COVID-19, inhibits

pro-inflammatory cytokine release, also known as the

cytokine storm

.

The presentation will summarize

evidence that treatment utilizing Ampion

suppresses Toll Like Receptor 7/8 (TLR7/8) signaling in

monocytic/macrophage

lineages and suggests

a role for Ampion in treating the dysregulation of these

pathways observed in lupus nephritis as well as in COVID-19. Toll Like Receptors are

fundamental, innate mechanisms to detect and respond to pathogens (pathogen-

associated molecular patterns, PAMPs, including viruses such as SARS-Cov2) or

damaged cells (damage-associated molecular patterns, DAMPs) by activating a

proinflammatory cascade in immune cells. Such dysregulated hyperactivation of

these pathways is associated with the cytokine/chemokine storm observed in

severe COVID-19 patients.

Ampio recently announced early positive data in its AP-014 Phase I clinical trial,

utilizing Ampion in treating respiratory distress in patients as a result of COVID-19.

The study showed inhaled Ampion reduced all-cause mortality in COVID-19

respiratory distress by 78% over the Standard of Care (SOC) alone.

For more information on the abstract presentation or LUPUS 2021 and CORA, visit

https://lupus2021.kenes.com/